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Background: Peroxisome proliferator-activated receptor coactivator-1α (PGC-1α) is an integrator of transcriptional circuits that regulates 
mitochondrial biogenesis and function. When activated, PGC-1α increases mitochondrial (MITO) oxidative capacity in the heart by increasing MITO 
number and expression of MITO enzymes. We previously showed that capadenoson (CAP), a partial adenosine A1-receptor agonist, improves LV 
function in dogs with heart failure (HF). This study examined the effects of CAP on phosphorylation and protein levels of PGC-1α in LV myocardium of 
HF dogs (LV ejection fraction 30%).
methods: LV tissue from 12 HF dogs randomized to 3 months oral monotherapy with CAP (7.5 mg twice daily, n=6) or to no therapy (HF-Control, 
n=6) and tissue from 6 normal (NL) dogs was used. Phosphorylated (p-) and total (t-) protein levels of PGC-1α and protein levels of β-actin, an 
internal control, were measured in LV homogenate by Western blotting.
results: β-actin was unchanged among study groups. Compared to NL, protein levels of p-PGC-1α and t-PGC-1α and the ratio of p- PGC-1α/t-
PGC-1α were significantly reduced in HF-Controls. Therapy with CAP normalized levels of p-PGC-1α and t- PGC-1α and the ratio of p- PGC-1α/t-
PGC-1α.
conclusions: Long-term therapy with CAP improves phosphorylation and total protein level of PGC-1α in LV myocardium of HF dogs. Improved 
myocardial energetics mediated by Improved PGC-1α regulation may explain the improvement of LV function seen following chronic CAP therapy.
TABLE
NL HF-Control HF-CAP
β-Actin (du) 0.64 ± 0.05 0.68 ± 0.05 0.65 ± 0.03
p- PGC-1α (du) 0.83 ± 0.10 0.23 ± 0.02* 0.78 ± 0.08†
t- PGC-1α (du) 0.40 ± 0.04 0.26 ± 0.02* 0.40 ± 0.04†
p- PGC-1α/t- PGC-1α 2.09 ± 0.14 0.88 ± 0.08* 2.01 ± 0.20†
du=densitometric units; *p<0.05 vs NL; †=p<0.05 vs. HF-Control
